WA-AMAZON-WEB-SERVICES
14.10.2021 06:03:11 CEST | Business Wire | Press release
Today, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that NXP Semiconductors N.V. has selected AWS as its preferred cloud provider and is migrating the vast majority of its electronic design automation (EDA) workloads from NXP data centers to AWS. Running on the world’s leading cloud extends NXP’s efficiency and competitive edge in the design and verification of advanced semiconductors tailored to the requirements of automotive, industrial Internet of Things (IoT), mobile, and communications infrastructure businesses. The Netherlands-based company uses AWS’s proven global infrastructure and capabilities in high performance computing (HPC), storage, analytics, and machine learning to enhance collaboration and EDA throughput across dozens of its worldwide design centers, as well as to reduce costs with elastic scaling of compute resources and minimize scheduling risks for design projects. In addition, thanks to AWS’s virtually unlimited scale, NXP engineers gain more time to focus on innovation rather than managing compute resources.
Running on AWS, NXP aims to achieve long-term process improvements that transform how semiconductors are designed and tested. Before NXP can manufacture new chips, its designs undergo extensive testing and validation through the EDA process to ensure they are functionally safe, secure, high quality, and highly performant. NXP’s complex EDA workflows include front-end design, performance simulation, and verification, along with backend workloads that include timing and power analysis, design rule checks, and other applications to prepare a chip for production. Historically, semiconductor companies run these highly iterative workflows from on-premises data centers with fixed compute capacity. However, because of the massive compute power involved for each cycle and the increasing complexity of chip designs, producing a new device can take many months or even years unless the companies accurately forecast and install additional compute infrastructure. In contrast, by powering its EDA with AWS, NXP gains the scale and agility to advance multiple projects at the same time on demand, regardless of their complexity, and run dozens of performance simulations in parallel to accelerate time to result.
To better manage the scale and complexity of its design activities, NXP relies on AWS analytics and machine learning services to continuously refine its research and development workflows. NXP uses Amazon QuickSight (AWS’s machine learning-powered business intelligence service built for the cloud) to generate more powerful engineering and operational insights that help increase workflow efficiency. For example, by rapidly translating results from one step of testing into modifications for another, NXP can reduce the time required to iterate chip designs. NXP also uses Amazon SageMaker (AWS’s service that helps developers and data scientists build, train, and deploy machine learning models quickly in the cloud and at the edge) to optimize how it structures compute, storage, and third-party software application licenses. To support this work, NXP is building a data lake on AWS using Amazon Simple Storage Service (Amazon S3) and AWS Glue (AWS’s service for simply and cost-effectively extracting, transforming, and loading data).
In addition, NXP takes advantage of AWS’s range of specialized instances for HPC to further streamline its EDA workflows. The selection of instance types allows NXP to meet the unique requirements of each design project while also achieving a high degree of price performance. NXP uses Amazon FSx for Lustre (AWS’s service that provides cost-effective, high-performance, scalable storage for compute workloads like EDA) to store petabytes of design simulation data and make it quickly available for analysis.
“We believe cloud-based EDA is critical to accelerating semiconductor innovation and getting new designs to market faster to power an increasingly digital world where more and more devices and infrastructure are connected. AWS gives us the best scale, global presence, and selection of compute and storage options, with continuous improvements in price performance, that we need,” said Olli Hyyppa, CIO and senior vice president, NXP Semiconductors N.V. “We’re excited to expand our relationship with AWS to power the next generation of EDA workloads in the cloud. This will give precious time back to our design engineers to focus on innovation and lead the transformation of the semiconductor industry.”
“At AWS, we consider ourselves to be a community of builders, and this engagement with NXP reinforces what’s possible when you free builders to work in the best environments, with the infrastructure and capabilities they need,” said Dave Brown, vice president of Amazon Elastic Compute Cloud, Amazon Web Services, Inc. “By shifting their EDA workloads to AWS, NXP designers will have access to the best tools available for collaborating on semiconductor design and development around the world. This move will help NXP produce chips that power innovation in IoT, connected cars, and more. We’re proud to support a leading driver of innovation in the semiconductor industry, and we look forward to seeing what becomes possible when chip design moves to the cloud at such a large scale.”
About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud offering. AWS has been continually expanding its services to support virtually any cloud workload, and it now has more than 200 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 81 Availability Zones within 25 geographic regions, with announced plans for 24 more Availability Zones and eight more AWS Regions in Australia, India, Indonesia, Israel, New Zealand, Spain, Switzerland, and the United Arab Emirates. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com
.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about
and follow @AmazonNews.
About NXP Semiconductors
NXP Semiconductors N.V. (NASDAQ: NXPI) enables secure connections for a smarter world, advancing solutions that make lives easier, better, and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the automotive, industrial & IoT, mobile, and communication infrastructure markets. Built on more than 60 years of combined experience and expertise, the company has approximately 29,000 employees in more than 30 countries and posted revenue of $8.61 billion in 2020. Find out more at www.nxp.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013006195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
